Program
tocilizumab
Also written as “Tocilizumab”, “tocilizumab [RoActemra/Actemra]” and “MRA(Tocilizumab)”.
Its studies are mostly in Arthritis, Rheumatoid · Arthritis, Juvenile · COVID-19 · Scleroderma, Systemic · Giant Cell Arteritis, led by 9 companies.
Drug pageTocilizumab: every studyMany companies study it; this page follows only the 129 they lead. All 336 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Rocheits history only | 1162 open or running | phase 4since Nov 9, 2009 | Mar 25, 2005 | Jul 30, 2027phase 2 · NCT04524871 |
| Bio-Thera Solutions | 30 open or running | phase 3since Jan 22, 2019 | Jul 12, 2018 | none ahead |
| Bristol-Myers Squibbits history only | 22 open or running | phase 3since Jan 9, 2026 | Feb 7, 2025 | Nov 14, 2028phase 3 · NCT07335562 |
| Fresenius Kabiits history only | 20 open or running | phase 3since Aug 11, 2020 | Aug 30, 2017 | none ahead |
| JW Pharmaceuticalits history only | 20 open or running | phase 3since Sep 29, 2010 | Sep 29, 2010 | none ahead |
| Beijing VDJBioits history only | 10 open or running | phase 2since Jul 11, 2023 | Jul 11, 2023 | none ahead |
| Biogenits history only | 10 open or running | phase 1since Feb 8, 2024 | Feb 8, 2024 | none ahead |
| Celltrionits history only | 10 open or running | phase 3since Feb 2, 2023 | Feb 2, 2023 | none ahead |
| Mycenax Biotechits history only | 10 open or running | phase 1since Apr 11, 2018 | Apr 11, 2018 | none ahead |
Also a collaborator on its studies: Gilead Sciences, Pfizer, Adagene, Tempest Therapeutics, NiKang Therapeutics and Immune-Onc Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Bio-Thera Solutions only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 12, 2018First study: phase 1 study in Arthritis, RheumatoidFirst studyNCT03606876 · 138 enrolled · China
- Jan 22, 2019Phase 3 study in Arthritis, RheumatoidNCT03830203 · 621 enrolled · China
- Jul 20, 2023Phase 1 study in Healthy MenNCT05968508 · 300 enrolled · China
TargetBeta
“A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity”NCIt, by rule
“Interleukin-6 receptor alpha subunit inhibitor”ChEMBL 37, by rule
Other programs on IL6R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sarilumabrule | Sanofi | phase 4 | 27 |
Studies
All 3 Bio-Thera Solutions leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05968508Healthy Men · China | 1 | Completed | Oct 8, 2024 | 300 |
| NCT03830203Arthritis, Rheumatoid · China | 3 | Completed | Jan 5, 2021 | 621 |
| NCT03606876Arthritis, Rheumatoid · China | 1 | Completed | Jul 17, 2019 | 138 |
How it is read
Names in the registry
- “Tocilizumab”, 54 entries
- “tocilizumab [RoActemra/Actemra]”, 47 entries
- “MRA(Tocilizumab)”, 11 entries
- “tocilizumab”, 6 entries
- “MSB11456”, 2 entries
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 87 studies
- Arthritis, Juvenile, 16 studies
- COVID-19, 5 studies
- Scleroderma, Systemic, 3 studies
- Giant Cell Arteritis, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.